The federal government has placed new restrictions on the prescribing of medications containing the opioid hydrocodone. Effective Oct. 6, the U.S. Drug Enforcement Agency (DEA) has published a final rule…
Read More
Genelex’s progress toward eliminating adverse drug events has been honored by Seattle Business magazine with a 2014 Tech Impact Award. At the September 18 awards event, Genelex was given…
Read More
Health care providers have been granted a bit of flexibility in how they use certified electronic health records (EHR) technology in meeting federal Meaningful Use requirements for 2014. The Centers…
Read More
A recent study illuminates the prevalence of opioid painkiller use in a particularly vulnerable population: disabled Americans on Social Security disability insurance. The article, published in the September edition of…
Read More
The use of health information technology enhancements, such as clinical decision support tools, can help reduce adverse drug events (ADEs) in hospitals by between 27.3 and 69.2 percent, according to…
Read More
New research into the risks of three common antipsychotic drugs for the elderly suggests older patients are 73 percent more likely to experience acute kidney injury (AKI) while on any…
Read More
It’s tragic when a young life is haunted by the specter of a disease that causes chronic pain. Such afflictions affect child and family both, making the availability of caregiver…
Read More
Barbara Granoff, Founding Member of The Coalition Against Pediatric Pain (TCAPP), says her 15-year-old daughter's life was changed by the DNA drug sensitivity testing Genelex offers. Shira is living with…
Read More
Don’t be intimidated by the idea of starting to use pharmacogenetics in your clinic – the tools you need may already be at your disposal. The New England Healthcare Institute…
Read More
A worrisome trend continues. Despite medical and government efforts, opioid-related deaths continue to rise across the country. According to the CDC, drug overdose death rates have more than doubled in…
Read More
